Tag Archives | Pharma CI

2014 is the year of Immuno-Oncology

One of the hot topic of conversation amongst the VCs at the JP Morgan Healthcare conference in San Francisco this past week was the field of immuno-oncology. We have already seen significant excitement in anti-PD1/PD-L1 drugs and their early promise in melanoma, renal and lung cancers. Taking a more strategic view, however, the question is how will immuno-oncology change the treatment landscape on a broader scale?

Continue Reading
Miami Beach Lifeguard Tower

2014 Cancer Conference Calendar

For those on the cancer conference circuit, 2014 is the year of the west coast swing, with 3 major meetings in San Francisco and two in San Diego. Here’s our calendar of key cancer meetings that we plan to attend in person or write about on Biotech Strategy Blog and Pharma Strategy Blog.

Continue Reading

ECCO ESMO 2013 European Cancer Congress in Amsterdam

Next week sees the start of the 2013 European Cancer Congress in Amsterdam. ECCO have announced that King Willem-Alexander of the Netherlands will attend the opening ceremony, which is impressive. Now that most of the meeting abstracts are available online we are starting to focus on what data may be hot at the meeting.

Continue Reading

Obtain Insights from Cancer Conferences

Today, Biotech Strategy Blog launched a paywall where insights from cancer conferences will be available to subscribers who pay a fee for access. It’s the first in a series of online digital and print products that we will be launching in coming months. Sign up if you would like to obtain exclusive insights from 2013 European Cancer Congress, AACR Molecular Targets meeting in Boston and ASH annual meeting in New Orleans.

Continue Reading

The challenge of Tumor Lysis Syndrome in Hematology New Product Development

Tumor Lysis Syndrome (TLS) has been in the news recently as a result of two patient deaths in a chronic lymphocytic leukemia (CLL) clinical trial with AbbVie’s ABT-199, a novel BCL-2 inhibitor in early stages of development. What is TLS and why is this important in cancer research was subsequently analyzed by Icarus Consultants hematology industry expert, Sally Church, PhD on Pharma Strategy Blog.

Continue Reading

Seek Insights not Data Dumps

Data is now commoditized. While obtaining data is relatively easy, insights are a lot more expensive and difficult to generate. Why? They require the application of knowledge, deep understanding and expertise of the topic to analyze, conceptualize and visualize data, and then extrapolate what it means to a company or product. Making sense of data is what we do.

Continue Reading